Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:13:11.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study details of a phase II trial assessing the efficacy and safety of nivolumab and ipilimumab in treating patients with metastatic/recurrent adenoid cystic carcinoma (ACC) and non-ACC salivary gland cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:08.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' The new description provides examples of eligibility criteria, such as a person's general health condition or prior treatments, and includes a link for general information about clinical research.
    Difference
    44%
    Check dated 2024-05-22T21:02:17.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T23:01:08.000Z thumbnail image

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.